Ipilimumab associated hepatitis: Imaging and clinicopathologic findings

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 1071-1077

  Kim, Kyung Won ^a,b   Ramaiya, Nikhil H ^a   Krajewski, Katherine M ^a   Jagannathan, Jyothi P ^a   Tirumani, Sree Harsha ^a   Srivastava, Amitabh ^a   Ibrahim, Nageatte ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatitis; Imaging; Immune related adverse events; Ipilimumab; Pathology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; IPILIMUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE;

ACUTE HEPATITIS; ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BILE DUCT INJURY; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; DRUG FEVER; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIALITIS; FEMALE; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERNATIONAL NORMALIZED RATIO; LIVER CELL DAMAGE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER METASTASIS; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MONONUCLEAR CELL; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANLOBULAR HEPATITIS; PERIPORTAL EDEMA; PERIPORTAL LYMPHADENOPATHY; PERIVENULAR LYMPHOPLASMACYTIC INFILTRATE; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; TOXIC HEPATITIS; VOMITING; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HEPATITIS; HUMANS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880924237     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9939-6     Document Type: Article

References (13)

1. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723. doi: 10.1056/NEJMoa1003466
2. Hoos A, Ibrahim R, Korman A et al (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37(5):533-546. doi: 10.1053/j.seminoncol.2010.09.015
3. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 197(2):W241-W246. doi: 10.2214/AJR.10.6032
4. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. doi: 10.1200/JCO.2012.41.6750
5. Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37(5):499-507. doi: 10.1053/j.seminoncol.2010.09.007
6. Lyall A, Vargas HA, Carvajal RD, Ulaner G (2012) Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med 37(6):629-630. doi: 10.1097/RLU. 0b013e318248549a
7. Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197(6):W992-W1000. doi: 10.2214/AJR.10.6198
8. Mortele KJ, Segatto E, Ros PR (2004) The infected liver: radiologic-pathologic correlation. Radiographics 24(4):937-955. doi: 10.1148/rg.244035719
9. Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233-2240. doi: 10.1007/s10620-012-2140-5
10. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372-8377. doi: 10.1073/pnas.1533209100
11. O'Day SJ, Maio M, Chiarion-Sileni V et al (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21(8):1712-1717. doi: 10.1093/annonc/mdq013
12. Chmiel KD, Suan D, Liddle C et al (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29(9):e237-e240. doi: 10.1200/JCO.2010.32.2206
13. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368. doi: 10.1111/j.1600-065X.2008.00604.x